|
|
|
August 2008
- The U.S. Food and Drug Administration approves Viread® (tenofovir disoproxil fumarate) for chronic hepatitis B in adults.
April 2008
- The European Commission approves Viread® (tenofovir disoproxil fumarate) for chronic hepatitis B.
November 2007
- Gilead LG Life Sciences, Ltd. enter into an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases.
October 2007
- Gilead submits regulatory applications for Viread for the potential treatment of chronic hepatitis B to U.S., European Union, Turkey, Australia and New Zealand regulatory authorities.
- Atripla approved by Health Canada.
August 2007
- Acquired Cork, Ireland manufacturing facility from Nycomed
June 2007
|
- The U.S. FDA approves Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension.
|
May 2007
- Gilead’s Board of Directors approves a two-for-one stock split.
November 2006
- Gilead acquires Edmonton, Alberta-based Raylo Chemicals.
- Gilead acquires Westminster, Colorado-based Myogen Inc.
August 2006
- Gilead acquires Seattle, Washington-based Corus Pharma.
- Gilead announces licensing agreements with India-based companies for manufacturing and distribution of generic versions of Viread ® in the developing world.
July 2006
- The U.S. FDA approves Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) -- the first once-daily single tablet regimen for adults with HIV-1 infection.
March 2005
- Gilead expands its Access Program to include additional countries in the Caribbean and Latin America, meaning that 97 countries, representing an estimated 70 percent of the global HIV/AIDS epidemic, are now included in the company’s access effort.
- Gilead establishes non-profit Foundation, with a mission of improving access to healthcare for people around the world.
February 2005
- European Medicines Agency approves Truvada for the treatment of HIV in the European Union.
December 2004
- The U.S. FDA approves Macugen® for age-related macular degeneration (formerly known as NX 1838).
September 2004
- Gilead's Board of Directors approves a two-for-one stock split.
August 2004
June 2004
- Gilead Sciences is added to the S&P 500.
October 2003
- Emtriva is approved in the European Union for the treatment of HIV/AIDS.
July 2003
- The U.S. FDA approves Emtriva® (emtricitabine) for the treatment of HIV.
April 2003
- Gilead launches its Access Program to provide the anti-HIV therapy Viread® in 68 developing countries at significantly reduced prices.
March 2003
- Hepsera is approved in the European Union for the treatment of chronic hepatitis B.
January 2003
- Gilead acquires Durham, North Carolina-based Triangle Pharmaceuticals.
December 2002
- Gilead announces the launch of the Gilead Access Program, which provides Viread at significantly reduced prices in every country in Africa and in 15 additional countries in other parts of the world classified as “least” developed by the United Nations.
September 2002
- The U.S. FDA approves Hepsera® (adefovir dipivoxil) for the treatment of chronic hepatitis B.
February 2002
- Gilead's Board of Directors approves a two-for-one stock split.
- European Medicines Agency approves Viread for the treatment of HIV infection in the European Union.
January 2002
- Gilead reports first year of positive cash flow from operations.
December 2001
- OSI Pharmaceuticals acquires oncology assets from Gilead.
October 2001
- The U.S. FDA approves Viread® (tenofovir disoproxil fumarate) for the treatment of HIV infection.
February 2001
- Gilead's Board of Directors approves a two-for-one stock split.
March 2000
- The U.S. FDA approves AmBisome® for the treatment of cryptococcal meningitis in HIV-infected patients.
October 1999
- The U.S. FDA approves Tamiflu® (oseltamivir phosphate) for the treatment of influenza A and B in adults.
July 1999
- Gilead acquires Boulder, Colorado-based NeXstar Pharmaceuticals, Inc. and establishes international operations.
June 1996
- The U.S. FDA approves Vistide® (cidofovir injection) for treatment of CMV retinitis in patients with AIDS.
January 1992
- Gilead completes its initial public offering of 5.75 million shares of Common Stock, for total proceeds of $86.25 million.
November 1991
- Gilead in-licenses nucleotides form IOCB/Rega.
December 1990
- AmBisome® (amphotericin B) liposome for injection receives first approval in Europe for the treatment of severe fungal infections.
|
|
